Intrinsic activating properties of GP IIb/IIIa blockers (Q28189326)

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Identification of membrane proteins mediating the interaction of human platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Platelet integrin GPIIb/IIIa: structure-function correlations. An update and lessons from other integrins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Platelet glycoprotein IIb. Chromosomal localization and tissue expression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Specific roles for platelet surface glycoproteins in platelet function

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Integrins: a family of cell surface receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Adhesion receptors of the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Integrins: versatility, modulation, and signaling in cell adhesion

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Evaluation of platelet membrane glycoproteins in coronary artery disease : consequences for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Focal adhesions: a nexus for intracellular signaling and cytoskeletal dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Modulation of cell adhesion by changes in alpha L beta 2 (LFA-1, CD11a/CD18) cytoplasmic domain/cytoskeleton interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Cell adhesion to fibronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Micromanipulation of adhesion of phorbol 12-myristate-13-acetate-stimulated T lymphocytes to planar membranes containing intercellular adhesion molecule-1

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Bidirectional transmembrane modulation of integrin alphaIIbbeta3 conformations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Participation of tyrosine phosphorylation in cytoskeletal reorganization, alpha(IIb)beta(3) integrin receptor activation, and aspirin-insensitive mechanisms of thrombin-stimulated human platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021

Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900300-0

7 January 2021